Asset

Samidorphan

Alkermes plc Ordinary Shares

Revenue

No revenue reported in loaded filings.

Clinical trials (3)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT00800319phase1completed2008-12-012009-02-01Alkermes, Inc.ALK33-001: A Study of RDC-0313 Administered to Healthy Adults
NCT01098435phase2completed2010-05-012011-05-01Alkermes, Inc.ALK33-101: A Study of RDC-0313 (ALKS 33) in Adults With Binge Eating Disorder
NCT01366001phase1completed2011-08-012012-02-01Alkermes, Inc.ALK33BUP-101: Safety and Pharmacodynamic Effects of ALKS 33-BUP Administered Alone and When Co-administered With Cocaine

FDA applications (0)

This company has no applications containing this asset.

Marketed products (0)